Hoda Metwally

569 total citations
10 papers, 324 citations indexed

About

Hoda Metwally is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Hoda Metwally has authored 10 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Oncology and 3 papers in Hematology. Recurrent topics in Hoda Metwally's work include Protein Degradation and Inhibitors (10 papers), Ubiquitin and proteasome pathways (7 papers) and Peptidase Inhibition and Analysis (7 papers). Hoda Metwally is often cited by papers focused on Protein Degradation and Inhibitors (10 papers), Ubiquitin and proteasome pathways (7 papers) and Peptidase Inhibition and Analysis (7 papers). Hoda Metwally collaborates with scholars based in United States and Poland. Hoda Metwally's co-authors include Donna McEachern, Shaomeng Wang, Bo Wen, Duxin Sun, Lijie Zhao, Aleksas Matvekas, Lu Wang, Xin Han, Weiguo Xiang and Bukeyan Miao and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Nature Chemical Biology.

In The Last Decade

Hoda Metwally

10 papers receiving 321 citations

Peers

Hoda Metwally

ONCOL

HEMAT

PRM

GENET

Aleksas Matvekas United States

John Houston United States

BaoChau Le United States

Inchul You United States

Marek Wanior Germany

Tomoko Asatsuma‐Okumura Japan

Rongfang Wei China

Montserrat Pérez-Salvia Spain

Björn Häupl Germany

Kwong-Him To Canada

Aleksas Matvekas United States

Hoda Metwally

264 ×0.9

102 ×0.7

ONCOL

71 ×0.8

HEMAT

46 ×0.9

PRM

14 ×1.1

GENET

Citations per year, relative to Hoda Metwally Hoda Metwally (= 1×) peers Aleksas Matvekas

Countries citing papers authored by Hoda Metwally

Since Specialization

Citations

This map shows the geographic impact of Hoda Metwally's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hoda Metwally with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hoda Metwally more than expected).

Fields of papers citing papers by Hoda Metwally

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hoda Metwally. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hoda Metwally. The network helps show where Hoda Metwally may publish in the future.

Co-authorship network of co-authors of Hoda Metwally

This figure shows the co-authorship network connecting the top 25 collaborators of Hoda Metwally. A scholar is included among the top collaborators of Hoda Metwally based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hoda Metwally. Hoda Metwally is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Huang, Liyue, Angelo Aguilar, Biao Hu, et al.. (2025). MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose Administration. Journal of Medicinal Chemistry. 68(13). 13249–13267. 2 indexed citations

Zhou, Haibin, Longchuan Bai, Hoda Metwally, et al.. (2024). Abstract 3881: Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression. Cancer Research. 84(6_Supplement). 3881–3881. 1 indexed citations

Yang, Yiqing, Longchuan Bai, Mi Wang, et al.. (2024). Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader. Journal of Medicinal Chemistry. 68(5). 5125–5151. 9 indexed citations

Chen, Zhixiang, Mi Wang, Lijie Zhao, et al.. (2024). Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer. Journal of Medicinal Chemistry. 67(7). 5351–5372. 15 indexed citations

Chen, Zhixiang, Mi Wang, Longchuan Bai, et al.. (2024). Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression. Journal of Medicinal Chemistry. 67(7). 5275–5304. 16 indexed citations

Rej, Rohan Kalyan, Zhixiang Chen, Biao Hu, et al.. (2024). Abstract 4510: Potent and orally efficacious PROTAC degraders of estrogen receptor α (ERα). Cancer Research. 84(6_Supplement). 4510–4510. 2 indexed citations

Bai, Longchuan, Mi Wang, Donna McEachern, et al.. (2023). A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo. Nature Chemical Biology. 19(6). 703–711. 40 indexed citations

Chen, Zhixiang, Biao Hu, Rohan Kalyan Rej, et al.. (2023). Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity. Journal of Medicinal Chemistry. 66(17). 12559–12585. 25 indexed citations

Han, Xin, Lijie Zhao, Weiguo Xiang, et al.. (2021). Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry. 64(17). 12831–12854. 104 indexed citations

10.

Xiang, Weiguo, Lijie Zhao, Xin Han, et al.. (2021). Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. Journal of Medicinal Chemistry. 64(18). 13487–13509. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact